Cancer patients' immune systems are receiving a boost from checkpoint inhibitors and other laboratory-made antibodies, which train T cells to attack cancer. An expanded understanding of cancer, genetics and immunobiology could revolutionize treatment. A team of UArizona researchers and clinicians, including several BIO5 members, are working at the leading edge of this fast-moving field.
Related
